Compare ALEMBIC with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC vs FRESENIUS KABI ONCO. - Comparison Results

ALEMBIC     Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC FRESENIUS KABI ONCO. ALEMBIC/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 79.5 22.1 359.2% View Chart
P/BV x 6.9 3.1 220.2% View Chart
Dividend Yield % 0.1 0.0 -  

Financials

 ALEMBIC   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    ALEMBIC
Mar-18
FRESENIUS KABI ONCO.
Mar-13
ALEMBIC/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs72176 40.9%   
Low Rs3479 43.2%   
Sales per share (Unadj.) Rs4.737.7 12.5%  
Earnings per share (Unadj.) Rs6.15.1 119.8%  
Cash flow per share (Unadj.) Rs6.26.7 92.9%  
Dividends per share (Unadj.) Rs0.200-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs40.742.5 95.6%  
Shares outstanding (eoy) m267.03158.23 168.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.33.4 333.6%   
Avg P/E ratio x8.725.0 34.7%  
P/CF ratio (eoy) x8.518.9 44.8%  
Price / Book Value ratio x1.33.0 43.5%  
Dividend payout %3.30-   
Avg Mkt Cap Rs m14,13920,135 70.2%   
No. of employees `000NA1.2 0.0%   
Total wages/salary Rs m207703 29.5%   
Avg. sales/employee Rs ThNM5,176.2-  
Avg. wages/employee Rs ThNM610.4-  
Avg. net profit/employee Rs ThNM699.6-  
INCOME DATA
Net Sales Rs m1,2555,963 21.0%  
Other income Rs m37018 2,056.7%   
Total revenues Rs m1,6255,981 27.2%   
Gross profit Rs m1111,430 7.8%  
Depreciation Rs m38258 14.7%   
Interest Rs m2-26 -6.5%   
Profit before tax Rs m4421,216 36.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m24342 7.0%   
Profit after tax Rs m1,630806 202.2%  
Gross profit margin %8.924.0 36.9%  
Effective tax rate %5.428.1 19.3%   
Net profit margin %129.813.5 960.8%  
BALANCE SHEET DATA
Current assets Rs m1,8675,102 36.6%   
Current liabilities Rs m5912,385 24.8%   
Net working cap to sales %101.645.6 223.2%  
Current ratio x3.22.1 147.7%  
Inventory Days Days94150 62.8%  
Debtors Days Days74113 64.9%  
Net fixed assets Rs m1,7915,148 34.8%   
Share capital Rs m534158 337.6%   
"Free" reserves Rs m10,3246,556 157.5%   
Net worth Rs m10,8586,732 161.3%   
Long term debt Rs m41952 4.3%   
Total assets Rs m11,59110,388 111.6%  
Interest coverage x260.9-45.8 -569.9%   
Debt to equity ratio x00.1 2.7%  
Sales to assets ratio x0.10.6 18.9%   
Return on assets %14.17.5 187.5%  
Return on equity %15.012.0 125.4%  
Return on capital %15.214.6 104.0%  
Exports to sales %1.574.5 2.1%   
Imports to sales %21.024.8 84.7%   
Exports (fob) Rs m194,441 0.4%   
Imports (cif) Rs m2631,477 17.8%   
Fx inflow Rs m195,298 0.4%   
Fx outflow Rs m2641,772 14.9%   
Net fx Rs m-2443,525 -6.9%   
CASH FLOW
From Operations Rs m2361,274 18.5%  
From Investments Rs m-224-1,204 18.6%  
From Financial Activity Rs m-27-196 13.6%  
Net Cashflow Rs m-15-126 11.7%  

Share Holding

Indian Promoters % 64.0 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 0.2 0.3 66.7%  
FIIs % 9.7 9.6 101.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 9.1 286.8%  
Shareholders   54,701 42,599 128.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC With:   DISHMAN PHARMA  ELDER PHARMA  SUVEN LIFE SCIENCES  ALEMBIC PHARMA  WOCKHARDT  

Compare ALEMBIC With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 272 Points Higher; Hindalco, Hero MotoCorp & Wipro Surge Over 4%(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended higher.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

More Views on News

Most Popular

Power Grid's InvIT IPO: Key Points to Consider(Company Info)

Apr 23, 2021

In this article, we discuss the key reasons why the stock of Power Grid was in focus today.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC SHARE PRICE


May 6, 2021 (Close)

TRACK ALEMBIC

  • Track your investment in ALEMBIC with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC - BIOCON COMPARISON

COMPARE ALEMBIC WITH

MARKET STATS